Immune checkpoint inhibitors (ICI), such as CTLA-1, PD-1, and PD-L1, have emerged as a powerful oncologic treatment modality and have become a standard treatment for patients with different tumor types (1, 2). The gene discussed is CD274; the disease is neoplasm.